A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's ($GSK) MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection. The vaccine can also be used in babies aged 2 months through 18 months who live in communities battling outbreaks of meningococcal disease caused by serogroups C and Y, Reuters reports. The decision is unrelated to an outbreak of fungal meningitis that has been linked to tainted steroid injections and has so far killed 24 people. Story